These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 24685923)

  • 1. RE: Serum phospholipid fatty acids and prostate cancer risk in the SELECT trial.
    Suburu J; Lim K; Calviello G; Chen YQ
    J Natl Cancer Inst; 2014 Apr; 106(4):dju023. PubMed ID: 24685923
    [No Abstract]   [Full Text] [Related]  

  • 2. RE: Serum phospholipid fatty acids and prostate cancer risk in the SELECT trial.
    McCulloch M; Alvarez E; Gendreau R; Haney S; Harrelson J; Luo R
    J Natl Cancer Inst; 2014 Apr; 106(4):dju024. PubMed ID: 24685926
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.
    Taneja SS
    J Urol; 2014 Mar; 191(3):658. PubMed ID: 24522035
    [No Abstract]   [Full Text] [Related]  

  • 4. RE: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.
    Tokudome S; Ando R; Ichikawa Y; Ichikawa H; Imaeda N; Goto C; Tokudome Y; Okuyama H
    J Natl Cancer Inst; 2014 Apr; 106(4):dju020. PubMed ID: 24685933
    [No Abstract]   [Full Text] [Related]  

  • 5. RE: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.
    El-Bayoumy K; Thompson H; Manni A
    J Natl Cancer Inst; 2014 Apr; 106(4):dju017. PubMed ID: 24685921
    [No Abstract]   [Full Text] [Related]  

  • 6. RE: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.
    Brenna JT; Burdge GC; Crawford MA; Clayton P; Cunnane SC; Gow R; Hibbeln JR; Sinclair AJ; Stein J; Willatts P
    J Natl Cancer Inst; 2014 Apr; 106(4):dju015. PubMed ID: 24685922
    [No Abstract]   [Full Text] [Related]  

  • 7. RE: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.
    Harris WS; Davidson MH
    J Natl Cancer Inst; 2014 Apr; 106(4):dju019. PubMed ID: 24685928
    [No Abstract]   [Full Text] [Related]  

  • 8. RE: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.
    Torfadottir JE; Stampfer MJ; Mucci LA; Giovannucci EL
    J Natl Cancer Inst; 2014 Apr; 106(4):dju018. PubMed ID: 24685929
    [No Abstract]   [Full Text] [Related]  

  • 9. RE: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.
    Cleland LG; Proudman SM; James MJ
    J Natl Cancer Inst; 2014 Apr; 106(4):dju022. PubMed ID: 24685932
    [No Abstract]   [Full Text] [Related]  

  • 10. RE: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.
    McCarty MF; Dinicolantonio JJ; Lavie CJ; O'Keefe JH
    J Natl Cancer Inst; 2014 Apr; 106(4):dju014. PubMed ID: 24685931
    [No Abstract]   [Full Text] [Related]  

  • 11. Words of wisdom. Re: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.
    Chow K; Murphy DG
    Eur Urol; 2013 Dec; 64(6):1015-6. PubMed ID: 24209450
    [No Abstract]   [Full Text] [Related]  

  • 12. Words of wisdom: Re: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.
    Sosnowski R; Zawistowski J
    Eur Urol; 2014 May; 65(5):1012. PubMed ID: 24646497
    [No Abstract]   [Full Text] [Related]  

  • 13. What you should know about omega-3 fatty acids and prostate cancer.
    Stohs SJ; Goldberg K
    J Diet Suppl; 2014 Dec; 11(4):476-8. PubMed ID: 24689516
    [No Abstract]   [Full Text] [Related]  

  • 14. Omega-3 and prostate cancer: examining the pertinent evidence.
    McCarty MF; DiNicolantonio JJ; Lavie CJ; O'Keefe JH
    Mayo Clin Proc; 2014 Apr; 89(4):444-50. PubMed ID: 24613035
    [No Abstract]   [Full Text] [Related]  

  • 15. Response.
    Brasky TM; Thompson IM; King IB; Kristal AR
    J Natl Cancer Inst; 2014 Apr; 106(4):dju021. PubMed ID: 24685927
    [No Abstract]   [Full Text] [Related]  

  • 16. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.
    Brasky TM; Darke AK; Song X; Tangen CM; Goodman PJ; Thompson IM; Meyskens FL; Goodman GE; Minasian LM; Parnes HL; Klein EA; Kristal AR
    J Natl Cancer Inst; 2013 Aug; 105(15):1132-41. PubMed ID: 23843441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial.
    Brasky TM; Till C; White E; Neuhouser ML; Song X; Goodman P; Thompson IM; King IB; Albanes D; Kristal AR
    Am J Epidemiol; 2011 Jun; 173(12):1429-39. PubMed ID: 21518693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial.
    Nash SH; Schenk JM; Kristal AR; Goodman PJ; Lucia MS; Parnes HL; Thompson IM; Lippman SM; Song X; Gurel B; De Marzo A; Platz EA
    Cancer Prev Res (Phila); 2015 Jul; 8(7):590-6. PubMed ID: 25926387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The A-to-Z of omega-3. Why this fatty acid is a must for good health.
    Neithercott T
    Diabetes Forecast; 2009 Feb; 62(2):45-8. PubMed ID: 19326578
    [No Abstract]   [Full Text] [Related]  

  • 20. The association of fatty acids with prostate cancer risk.
    Newcomer LM; King IB; Wicklund KG; Stanford JL
    Prostate; 2001 Jun; 47(4):262-8. PubMed ID: 11398173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.